TY - JOUR
T1 - Long-acting injectable antipsychotic use in patients with bipolar disorder
T2 - Findings from the REAP-BD study
AU - Lin, Chun
AU - Lin, Yueh Pin
AU - Park, Seon Cheol
AU - Jang, Ok Jin
AU - Si, Tian Mei
AU - Xiang, Yu Tao
AU - Lin, Huang Li
AU - Javed, Afzal
AU - Sayeed Khan, M. Nasar
AU - Grover, Sandeep
AU - Kallivayali, Roy Abraham
AU - Chee, Kok Yoon
AU - Kato, Takahiro A.
AU - Pariwatcharakul, Pornjira
AU - Maramis, Margarita
AU - Seneviratne, Lakmi
AU - Sim, Kang
AU - Tang, Wai Kwong
AU - Oo, Tin
AU - Sartorius, Norman
AU - Tan, Chay Hoon
AU - Mian-Yoon,
AU - Shinfuku, Naotaka
AU - Lin, Shih Ku
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2025/1
Y1 - 2025/1
N2 - Aims: This study aimed to assess treatment patterns and the effectiveness of long-acting injectable antipsychotics (LAIs) in patients with bipolar disorder (BD) across various Asian countries. The study focused on comparing the choices of LAIs, other psychotropic medications, and their psychotropic drug load to explore real-world usage and evaluate the potential benefits of LAIs in BD treatment across different countries. Methods: A retrospective cohort study was conducted with BD patients diagnosed according to ICD-10-CM codes F31.0 to F31.9 across 13 Asian countries or regions. Data were collected through an online system covering prescriptions for all psychotropic medications including LAIs. The Anatomical Therapeutic Chemical (ATC) Classification System was used to compare medication dosage patterns. Results: The study analyzed 2029 prescription records for BD, including 103 cases involving LAIs. The highest LAI prescription rates were found in Sri Lanka and Malaysia, with no reported use in Myanmar, India, and Japan. Patients receiving LAIs were younger, more often male, and had higher BMI and drug loads compared to those on oral medications. South Korea and Indonesia showed the highest LAIs drug load. South Korea, Pakistan, and China exhibited the highest total psychotropic drug loads, while Malaysia had the lowest. Conclusions: This study is the first to examine LAIs use for BD across Asia. Cross-national differences in LAIs prescriptions and psychotropic drug load highlight variations in treatment practices and healthcare systems. These findings underscore the need for further research and the development of region-specific guidelines to improve BD treatment outcomes.
AB - Aims: This study aimed to assess treatment patterns and the effectiveness of long-acting injectable antipsychotics (LAIs) in patients with bipolar disorder (BD) across various Asian countries. The study focused on comparing the choices of LAIs, other psychotropic medications, and their psychotropic drug load to explore real-world usage and evaluate the potential benefits of LAIs in BD treatment across different countries. Methods: A retrospective cohort study was conducted with BD patients diagnosed according to ICD-10-CM codes F31.0 to F31.9 across 13 Asian countries or regions. Data were collected through an online system covering prescriptions for all psychotropic medications including LAIs. The Anatomical Therapeutic Chemical (ATC) Classification System was used to compare medication dosage patterns. Results: The study analyzed 2029 prescription records for BD, including 103 cases involving LAIs. The highest LAI prescription rates were found in Sri Lanka and Malaysia, with no reported use in Myanmar, India, and Japan. Patients receiving LAIs were younger, more often male, and had higher BMI and drug loads compared to those on oral medications. South Korea and Indonesia showed the highest LAIs drug load. South Korea, Pakistan, and China exhibited the highest total psychotropic drug loads, while Malaysia had the lowest. Conclusions: This study is the first to examine LAIs use for BD across Asia. Cross-national differences in LAIs prescriptions and psychotropic drug load highlight variations in treatment practices and healthcare systems. These findings underscore the need for further research and the development of region-specific guidelines to improve BD treatment outcomes.
KW - Antipsychotic
KW - Bipolar disorder
KW - Long-acting injectable
KW - Psychotropic drug load
KW - REAP
UR - http://www.scopus.com/inward/record.url?scp=85211243394&partnerID=8YFLogxK
U2 - 10.1016/j.ajp.2024.104338
DO - 10.1016/j.ajp.2024.104338
M3 - Article
AN - SCOPUS:85211243394
SN - 1876-2018
VL - 103
JO - Asian Journal of Psychiatry
JF - Asian Journal of Psychiatry
M1 - 104338
ER -